Methoxyacetyl-Fentanyl Stats & Data

Methoxyacetylfentanyl, commonly abbreviated as MAF, emerged as part of a broader wave of synthetic opioid designer drugs that appeared on online markets during the 2010s. The substance belongs to a class of fentanyl analogs that have been associated with significant public health concerns across multiple regions. The proliferation of novel fentanyl derivatives has occurred in distinct waves across different geographic regions. The first major resurgence began in Estonia and spread through Europe and former Soviet republics in the early 2000s, resulting in hundreds of fatalities. A second wave emerged around 2014 in the United States, with the prevalence and associated mortality escalating substantially from 2016 onward. In response to mounting concerns about novel synthetic opioids, methoxyacetylfentanyl was placed into Schedule I of the Controlled Substances Act in the United States in October 2017, a measure taken to address what regulators described as an imminent hazard to public safety.